MCM
NBIX icon

Mazama Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Mazama Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,762
Closed -$326K – 114
2015
Q4 		$326K Buy
+5,762
New +$293K 0.06% 191

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Mazama Capital Management's NBIX Position: Q1 2016 in Review

Mazama Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2016, closing a stake of 5,762 shares — an estimated $326K sold.

Mazama Capital Management first reported a position in NBIX in Q4 2015 and held it in 1 quarter. The position peaked at $326K in Q4 2015. 213 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

  • Mazama Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2016 after selling out during the quarter.
  • Mazama Capital Management sold 5,762 Neurocrine Biosciences shares in Q1 2016, an estimated $326K.
  • Mazama Capital Management first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 1 quarter.
  • Mazama Capital Management's Neurocrine Biosciences position peaked at $326K in Q4 2015.
  • 213 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.